Investment analysts at JMP Securities initiated coverage on shares of ABIVAX Société Anonyme (NASDAQ:ABVX – Get Free Report) in a research report issued on Wednesday, MarketBeat Ratings reports. The firm set an “outperform” rating and a $33.00 price target on the stock. JMP Securities’ price objective indicates a potential upside of 296.16% from the company’s current price.
ABIVAX Société Anonyme Trading Down 6.3 %
ABVX opened at $8.33 on Wednesday. The firm’s 50 day moving average is $9.85 and its 200-day moving average is $11.61. ABIVAX Société Anonyme has a 52-week low of $8.06 and a 52-week high of $17.02.
Institutional Trading of ABIVAX Société Anonyme
Institutional investors have recently added to or reduced their stakes in the stock. abrdn plc raised its holdings in ABIVAX Société Anonyme by 167.7% in the third quarter. abrdn plc now owns 316,431 shares of the company’s stock valued at $3,645,000 after acquiring an additional 198,225 shares in the last quarter. Walleye Capital LLC raised its holdings in ABIVAX Société Anonyme by 45.8% in the third quarter. Walleye Capital LLC now owns 257,417 shares of the company’s stock valued at $2,965,000 after acquiring an additional 80,807 shares in the last quarter. BNP Paribas Financial Markets raised its holdings in ABIVAX Société Anonyme by 82.6% in the third quarter. BNP Paribas Financial Markets now owns 13,044 shares of the company’s stock valued at $150,000 after acquiring an additional 5,900 shares in the last quarter. Finally, Point72 Asset Management L.P. raised its holdings in ABIVAX Société Anonyme by 28.2% in the third quarter. Point72 Asset Management L.P. now owns 542,900 shares of the company’s stock valued at $6,254,000 after acquiring an additional 119,300 shares in the last quarter. 47.91% of the stock is owned by institutional investors and hedge funds.
About ABIVAX Société Anonyme
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.
See Also
- Five stocks we like better than ABIVAX Société Anonyme
- Differences Between Momentum Investing and Long Term Investing
- NVIDIA’s Blackwell Chips Set for Arizona Manufacturing by TSMC?
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Okta: Bullish Signals Suggest a Market Reversal Is Underway
- What is the Australian Securities Exchange (ASX)
- BlackRock Makes Waves With $12B Private Credit Acquisition
Receive News & Ratings for ABIVAX Société Anonyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIVAX Société Anonyme and related companies with MarketBeat.com's FREE daily email newsletter.
